About: Effect of long-term hormone replacement therapy on tissue factor pathway inhibitor and thrombin activatable fibrinolysis inhibitor in healthy postmenopausal women: a randomized controlled study

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Effect of long-term hormone replacement therapy on tissue factor pathway inhibitor and thrombin activatable fibrinolysis inhibitor in healthy postmenopausal women: a randomized controlled study Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 01 June 2003

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована в травні 2003 (uk) im Juni 2003 veröffentlichter wissenschaftlicher Artikel (de) article scientifique publié en 2003 (fr) artículu científicu espublizáu en xunu de 2003 (ast) scientific article published on 01 June 2003 (en)
publication date	wds:Q59057086-019FE55A-55B4-4D35-8824-C739E018EAC2
publication date	2003-06-01 00:00:00Z (xsd:dateTime)
cites work	wds:Q59057086-0FEE74BD-61A4-4545-BD34-9FD43E499D0B wds:Q59057086-10CC6A92-712D-4A00-A871-137CA691E044 wds:Q59057086-17DD10A8-507C-4AE7-A851-2CFF6048911F wds:Q59057086-32154B3B-95EE-4DC0-80D7-B1F1AF67250A wds:Q59057086-453AC238-99E9-4B16-BE83-FADA0DB9EC59 wds:Q59057086-48AD4FF6-05AC-46F7-AB2D-4BD966762FC4 wds:Q59057086-5166AF12-4704-4F1F-B61E-E0F20AE7311B wds:Q59057086-58EEEC01-5540-42C0-86FC-57A48F0F833E wds:Q59057086-5F61ABC4-3AB9-423E-9F71-0BC8774C5BD7 wds:Q59057086-68770F4B-D8B5-486A-98A4-BEC18CBDD8AA wds:Q59057086-6B2FCB1D-14BD-4219-9A87-B92AD458E9F5 wds:Q59057086-73DDF8F0-3DA6-4DC0-BA1F-16ECD208BA05 wds:Q59057086-82533533-9E37-402E-8CD9-7ABFAB71BE58 wds:Q59057086-8389621C-5C8E-4282-BFBD-6FCC8E33FA19 wds:Q59057086-A554E07F-5745-4C59-A213-0B51B8EBDCE9 wds:Q59057086-AF3FFA4C-B692-4E9C-AAE5-457209759D56 wds:Q59057086-C093289B-540A-46F3-A3A3-7C76739CB8BC wds:Q59057086-CBAAF7C3-C23F-4015-A4B0-01CB5CBA17E2 wds:Q59057086-D4DE46BA-5338-4CFB-B671-94FC1FA3D722 wds:Q59057086-D71B73B1-9868-438C-9AC4-534CD2FF4308
cites work	Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II) Hormone replacement therapy, heart disease, and other considerations. Decreased plasma tissue factor pathway inhibitor in women taking combined oral contraceptives Tissue-factor antigen and activity in human coronary atherosclerotic plaques Effects of hormone-replacement therapy on fibrinolysis in postmenopausal women Plasma thrombin-activatable fibrinolysis inhibitor antigen concentration and genotype in relation to myocardial infarction in the north and south of Europe Differential effects of oral and transdermal estrogen replacement therapy on endothelial function in postmenopausal women Identification of polymorphisms in the promoter and the 3' region of the TAFI gene: evidence that plasma TAFI antigen levels are strongly genetically controlled Oral oestradiol/trimegestone replacement reduces procarboxypeptidase U (TAFI): a randomized, placebo- controlled, 12-week study in early postmenopausal women Effect of long-term hormone replacement therapy on plasma homocysteine in postmenopausal women: a randomized controlled study Effects of different progestin regimens in hormone replacement therapy on blood coagulation factor VII and tissue factor pathway inhibitor. The Danish Osteoporosis Prevention Study (DOPS): project design and inclusion of 2000 normal perimenopausal women Association of hormone replacement therapy with hemostatic and other cardiovascular risk factors. The FINRISK Hemostasis Study Long-term effect of 17beta-estradiol and thrombin on tissue factor pathway inhibitor release from HUVEC Thrombogenic potential of human coronary atherosclerotic plaques Thrombin-activatable fibrinolysis inhibitor antigen levels and cardiovascular risk factors Treatment with hydroxymethylglutaryl-coenzyme A reductase inhibitors in hypercholesterolemia induces changes in the components of the extrinsic coagulation system
author name string	wds:Q59057086-3925514A-906E-41B2-879A-22BB0AA1C4B1 wds:Q59057086-48178628-833F-4FF6-8B25-83C686CE419B wds:Q59057086-F780DD7B-9C74-4B6B-8B35-7CD15E0D350A
author name string	Mosekilde L Brixen K Kristensen SR
rdfs:label	Effect of long-term hormone replacement therapy on tissue factor pathway inhibitor and thrombin activatable fibrinolysis inhibitor in healthy postmenopausal women: a randomized controlled study (en) Effect of long-term hormone replacement therapy on tissue factor pathway inhibitor and thrombin activatable fibrinolysis inhibitor in healthy postmenopausal women: a randomized controlled study (nl)
skos:prefLabel	Effect of long-term hormone replacement therapy on tissue factor pathway inhibitor and thrombin activatable fibrinolysis inhibitor in healthy postmenopausal women: a randomized controlled study (en) Effect of long-term hormone replacement therapy on tissue factor pathway inhibitor and thrombin activatable fibrinolysis inhibitor in healthy postmenopausal women: a randomized controlled study (nl)
name	Effect of long-term hormone replacement therapy on tissue factor pathway inhibitor and thrombin activatable fibrinolysis inhibitor in healthy postmenopausal women: a randomized controlled study (en) Effect of long-term hormone replacement therapy on tissue factor pathway inhibitor and thrombin activatable fibrinolysis inhibitor in healthy postmenopausal women: a randomized controlled study (nl)
author	wds:Q59057086-19C00561-B999-485B-ACB7-6CF231824CF1 wds:Q59057086-1FDEDA0D-9662-4A49-B52A-DE2FAB3456EB wds:Q59057086-212C311B-FB4D-4502-A1DC-1214B90DFE9B wds:Q59057086-A8758886-F652-48E0-91B8-7B3C9983DF3C
author	Bo Abrahamsen Jørgen Jespersen Jonna S Madsen Else Bladbjerg
title	wds:Q59057086-452BE71C-BC0A-4AA6-8489-15D56474077A
title	Effect of long-term hormone replacement therapy on tissue factor pathway inhibitor and thrombin activatable fibrinolysis inhibitor in healthy postmenopausal women: a randomized controlled study (en)
page(s)	wds:Q59057086-DB6D2FA0-BC15-419B-A1A0-98081AD24799
page(s)	1208-1214
instance of	wds:Q59057086-BF7C543A-B76B-4FDF-8D9E-2A2A1C7A893F
instance of	scholarly article
main subject	wds:Q59057086-009C5DD5-5D5C-4172-B412-24C7130A8FAE
main subject	Hormone Replacement Therapy
PubMed ID	wds:Q59057086-D77222C9-9AB1-484C-8004-35D0AB1CD1DC
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/12871321
PubMed ID	12871321
published in	wds:Q59057086-C9A1CB58-FD8A-4F88-9ADF-0A1B5686B042
published in	Journal of Thrombosis and Haemostasis
issue	wds:Q59057086-749EF331-EF17-48C2-AA9D-0BF90BA3DE95
volume	wds:Q59057086-E865CC52-B6B6-4521-83A8-21E3967D2B77
issue	6
volume	1
DOI	wds:Q59057086-1B29A78D-3B05-49F4-B966-543A69780104
DOI	http://dx.doi.org/10.1046/J.1538-7836.2003.00281.X
DOI	10.1046/J.1538-7836.2003.00281.X
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q59057086
is cites work of	Novel protein ADTRP regulates TFPI expression and function in human endothelial cells in normal conditions and in response to androgen Meta-analysis: effect of hormone-replacement therapy on components of the metabolic syndrome in postmenopausal women Hormone therapy for preventing cardiovascular disease in post-menopausal women Genetic influence on thrombotic risk markers in the elderly--a Danish twin study. Emerging selective estrogen receptor modulators: special focus on effects on coronary heart disease in postmenopausal women HMR 3339, a novel selective estrogen receptor modulator, reduces concentrations of procarboxypeptidase U, an inhibitor of fibrinolysis. A randomized, placebo-controlled study in postmenopausal women Tissue Factor Pathway Inhibitor, Activated Protein C Resistance, and Risk of Coronary Heart Disease Due To Combined Estrogen Plus Progestin Therapy Tissue factor and tissue factor pathway inhibitor as key regulators of global hemostasis: measurement of their levels in coagulation assays Low levels of tissue factor pathway inhibitor increase the risk of cerebral venous thrombosis Risk of venous thromboembolic disease in postmenopausal women taking oral or transdermal hormone replacement therapy

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 171 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software